Daptomycin
daptomycin for injection (Cubicin, Cubicin RF)
Indications
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| Complicated skin and skin structure infections (cSSSI) caused by S. aureus (MRSA/MSSA), S. pyogenes, S. agalactiae, S. dysgalactiae subsp. equisimilis, and E. faecalis (vancomycin-susceptible only) | Adults and pediatrics 1–17 years | Monotherapy | FDA Approved |
| S. aureus bloodstream infections (bacteremia) including right-sided infective endocarditis, caused by MSSA and MRSA | Adults and pediatrics 1–17 years | Monotherapy | FDA Approved |
Daptomycin is the first cyclic lipopeptide antibiotic, approved in 2003. It provides rapid concentration-dependent bactericidal activity against Gram-positive organisms, including MRSA and VRE. Its unique mechanism of action — calcium-dependent insertion into the bacterial cell membrane causing depolarisation — means cross-resistance with other antibiotic classes is uncommon. Daptomycin is available only as an IV formulation because it is not orally absorbed. Two critical limitations govern its use: it is inactivated by pulmonary surfactant and therefore must not be used for pneumonia, and it is not approved for left-sided infective endocarditis.
VRE infections (including bacteremia and endocarditis): Daptomycin is active against E. faecium and E. faecalis, including vancomycin-resistant strains. Frequently used off-label for VRE bacteremia. Evidence quality: Moderate (IDSA guidelines; observational studies).
Left-sided endocarditis (salvage therapy): Used off-label, often at high doses (8–12 mg/kg) and in combination with a beta-lactam (e.g., ceftaroline) for persistent MRSA bacteremia or left-sided endocarditis failing standard therapy. Evidence quality: Moderate (cohort studies; IDSA guideline recommends considering high-dose daptomycin).
Bone and joint infections (MRSA): Used as part of combination therapy for MRSA osteomyelitis and prosthetic joint infections. Evidence quality: Moderate (IDSA guideline 2011; cohort studies).
Febrile neutropenia (empiric Gram-positive cover): Considered when Gram-positive cover is needed and vancomycin/linezolid are contraindicated. Evidence quality: Low (limited data).
Dosing
Adult Dosing — By Clinical Scenario
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Complicated SSTI (MRSA, MSSA, streptococci, VSE) | 4 mg/kg IV q24h | 4 mg/kg IV q24h | 4 mg/kg/day (FDA-approved) | Duration: 7–14 days Administer as 2-min IV push or 30-min infusion in 0.9% NaCl |
| S. aureus bacteremia / right-sided endocarditis | 6 mg/kg IV q24h | 6 mg/kg IV q24h | 6 mg/kg/day (FDA-approved) | Duration: 2–6 weeks Limited safety data beyond 28 days |
| Persistent MRSA bacteremia / complicated endocarditis (off-label high-dose) | 8–10 mg/kg IV q24h | 8–12 mg/kg IV q24h | 12 mg/kg/day (off-label) | Used for salvage therapy or high-inoculum infections; often combined with ceftaroline or a beta-lactam Monitor CPK more frequently; well-tolerated up to 12 mg/kg in Phase 1 studies |
| VRE bacteremia (off-label) | 8–12 mg/kg IV q24h | 8–12 mg/kg IV q24h | 12 mg/kg/day (off-label) | Higher doses often used based on PK/PD data for enterococci Combination with ampicillin (for E. faecalis) or ceftaroline may enhance activity |
| Renal impairment (CrCl <30 mL/min, HD, CAPD) | 4 mg/kg (cSSSI) or 6 mg/kg (bacteremia) IV q48h | Same dose, q48h | As per indication | Administer after haemodialysis on dialysis days ~15% removed by 4h HD; ~11% by 48h PD |
Pediatric Dosing (1–17 Years) — cSSSI
| Age Group | Dose | Frequency | Maximum Dose | Notes |
|---|---|---|---|---|
| 1 to <2 years | 10 mg/kg IV | Once daily | 10 mg/kg | Duration: up to 14 days; infusion over 60 minutes Highest weight-based dose due to fastest clearance in this age group |
| 2–6 years | 9 mg/kg IV | Once daily | 9 mg/kg | Duration: up to 14 days; infusion over 60 minutes |
| 7–11 years | 7 mg/kg IV | Once daily | 7 mg/kg | Duration: up to 14 days; infusion over 30 minutes |
| 12–17 years | 5 mg/kg IV | Once daily | 5 mg/kg | Duration: up to 14 days; infusion over 30 minutes |
Pediatric Dosing (1–17 Years) — S. aureus Bacteremia
| Age Group | Dose | Frequency | Maximum Dose | Notes |
|---|---|---|---|---|
| 1–6 years | 12 mg/kg IV | Once daily | 12 mg/kg | Duration: up to 42 days; infusion over 60 minutes Do NOT administer as 2-min IV push in pediatric patients |
| 7–11 years | 9 mg/kg IV | Once daily | 9 mg/kg | Duration: up to 42 days; infusion over 30 minutes |
| 12–17 years | 7 mg/kg IV | Once daily | 7 mg/kg | Duration: up to 42 days; infusion over 30 minutes |
The FDA-approved dose for bacteremia (6 mg/kg) was established in trials comparing daptomycin to standard of care. However, clinical experience and PK/PD data strongly support using higher doses (8–12 mg/kg) for serious infections, particularly persistent bacteremia, endocarditis, and deep-seated infections. In a Phase 1 study, daptomycin was well tolerated at doses up to 12 mg/kg daily for 14 days. Combination with beta-lactams (especially ceftaroline) has shown synergistic killing of MRSA in both in vitro and clinical data, and may prevent the emergence of daptomycin non-susceptibility. The IDSA MRSA guideline recommends considering high-dose daptomycin (10 mg/kg) with an anti-staphylococcal beta-lactam for persistent MRSA bacteremia.
Pharmacology
Mechanism of Action
Daptomycin is a cyclic lipopeptide antibiotic derived from Streptomyces roseosporus with a unique, calcium-dependent mechanism of action. In the presence of physiological calcium concentrations, daptomycin inserts its lipophilic tail into the Gram-positive bacterial cell membrane, forming oligomeric pores that cause rapid membrane depolarisation. This leads to loss of the membrane potential, cessation of DNA, RNA, and protein synthesis, and rapid cell death without lysis. Because daptomycin kills bacteria through membrane disruption rather than inhibition of a specific enzymatic pathway, its mechanism is distinct from all other antibiotic classes, and cross-resistance is rare. Daptomycin exhibits concentration-dependent bactericidal activity, with the AUC/MIC ratio being the PK/PD parameter best correlated with efficacy.
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | Not orally absorbed; IV administration only; inactivated by pulmonary surfactant | No oral formulation exists; cannot be used for pneumonia regardless of pathogen susceptibility |
| Distribution | Vd ~0.1 L/kg; protein binding 90–93%; primarily distributed in plasma with limited tissue penetration | Small Vd means drug concentrates in plasma; achieves high serum bactericidal levels; limited penetration into lung, CSF, and some deep tissues |
| Metabolism | Minimal hepatic metabolism; not a CYP substrate, inhibitor, or inducer | Negligible CYP-mediated drug interactions; no dose adjustment for hepatic impairment |
| Elimination | ~78% renal excretion (52% as unchanged drug); t½ ~8 h; ~15% removed by 4h HD; ~11% by 48h PD | Primarily renally cleared; extend dosing interval to q48h for CrCl <30 mL/min; administer after haemodialysis on dialysis days; linear PK through 6 mg/kg |
Side Effects
Safety data from Phase 3 cSSSI trials (n=534 daptomycin 4 mg/kg) and the Phase 3 S. aureus bacteremia/endocarditis trial (n=120 daptomycin 6 mg/kg). Adverse event profiles differ between indications due to different doses and treatment durations.
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Headache | 5.4% | Non-specific; similar to comparator |
| Diarrhea | 5.2% | Mild; distinguish from CDAD; lower risk than vancomycin |
| Rash | 4.3% | Usually maculopapular; discontinue if signs of serious reaction |
| Abnormal LFTs | 3.0% | Monitor hepatic function; usually transient |
| Elevated CPK | 2.8% | vs 1.8% comparator; only 0.2% had symptomatic myopathy |
| UTI | 2.4% | Non-specific; consider in hospitalised patients |
| Hypotension | 2.4% | Monitor during infusion |
| Dizziness | 2.2% | Non-specific |
| Dyspnoea | 2.1% | Distinguish from eosinophilic pneumonia |
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Insomnia | 9% | May reflect underlying severity of illness |
| Pharyngolaryngeal pain | 8% | Non-specific |
| Chest pain | 7% | Assess for endocarditis-related vs drug-related |
| Edema | 7% | Non-specific |
| Elevated CPK | 7% | CPK >500 U/L in 9.2% (vs 0.9% comparator); monitor weekly |
| Abdominal pain | 6% | Assess for intra-abdominal complications |
| Pruritus | 6% | Distinguish from hypersensitivity reaction |
| Hypertension | 6% | Monitor blood pressure |
| Sepsis / bacteremia | 5% each | May reflect underlying disease course; serious Gram-negative infections reported in 8.3% of daptomycin-treated vs 0% comparator |
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| Myopathy / rhabdomyolysis | CPK >10× ULN: uncommon at approved doses; risk increases with higher doses and concurrent statins | Days to weeks; dose- and duration-dependent | Monitor CPK weekly; discontinue if CPK >5× ULN with symptoms (myalgia, weakness) or >10× ULN without symptoms; suspend statins during therapy; symptoms resolve within 3 days and CPK normalises within 7–10 days of stopping |
| Eosinophilic pneumonia | Rare (postmarketing reports) | Usually 2–4 weeks after initiation | Suspect if new fever, dyspnoea, pulmonary infiltrates, and peripheral eosinophilia develop during therapy; discontinue daptomycin immediately; corticosteroids may be needed; do not rechallenge |
| Anaphylaxis / hypersensitivity | Rare (postmarketing) | Any time during therapy | Discontinue immediately; institute appropriate emergency therapy |
| Peripheral neuropathy | Uncommon (postmarketing) | Variable | Monitor for numbness, tingling, or burning; consider discontinuation if symptoms develop |
| Serious Gram-negative infections | 8.3% in bacteremia trial (vs 0% comparator) | During or after therapy | Daptomycin has no Gram-negative activity; ensure Gram-negative coverage when mixed infections are possible; monitor for superinfection |
| CDAD | Uncommon | During or up to 2 months after therapy | Test for C. difficile toxin if diarrhea develops; manage per guidelines |
CPK elevation is the signature toxicity of daptomycin and is dose- and frequency-dependent. At the approved 4 mg/kg dose for cSSSI, clinically relevant CPK elevation occurs in approximately 2.8% of patients. At 6 mg/kg for bacteremia, CPK >500 U/L occurs in 9.2%. The critical distinction is between asymptomatic CPK elevation (which may not require discontinuation if <10× ULN) and symptomatic myopathy (muscle pain/weakness), which mandates immediate discontinuation. When CPK is monitored weekly and daptomycin is dosed at q24h intervals (not more frequently), myopathy is generally reversible. The original q12h dosing explored in early trials caused unacceptable myopathy, leading to the once-daily regimen.
Drug Interactions
Daptomycin has a limited drug interaction profile because it is not metabolised by CYP450 enzymes and does not inhibit or induce them. Its primary interactions are pharmacodynamic (additive myotoxicity with statins) and analytical (false PT/INR elevation).
Monitoring
- CPK (Creatine Phosphokinase)Baseline, then weekly
RoutineThe single most important monitoring parameter. Discontinue if CPK >5× ULN with symptoms (myalgia, weakness) or >10× ULN without symptoms. Monitor more frequently if concurrent statin, renal impairment, or prior/concomitant statin therapy. Also monitor more frequently at off-label higher doses (>6 mg/kg). - Renal FunctionBaseline, then weekly
RoutineDaptomycin is primarily renally cleared; accumulation in renal impairment increases CPK elevation risk. Extend dosing interval to q48h if CrCl drops below 30 mL/min during treatment. Rhabdomyolysis (with or without AKI) has been reported. - Blood CulturesEvery 48–72 hours until clearance (bacteremia)
RoutinePersistent or relapsing bacteremia may indicate reduced daptomycin susceptibility. Repeat susceptibility testing on any new positive culture. Consider high-dose daptomycin, combination therapy, or alternative agent if bacteremia persists >3–5 days. - Respiratory SymptomsThroughout treatment
Trigger-basedEosinophilic pneumonia can develop (typically 2–4 weeks into therapy). Suspect if new fever, cough, dyspnoea, and infiltrates appear during treatment. Obtain CBC with differential (peripheral eosinophilia), chest imaging, and BAL if feasible. Discontinue daptomycin immediately if suspected. - Musculoskeletal SymptomsAt each visit / weekly
RoutineAsk about muscle pain, tenderness, or weakness (particularly distal extremities) at each assessment. Correlate with CPK levels. - PT/INRIf on concurrent anticoagulation
Trigger-basedDraw specimens at trough (just before next dose) to minimise the artefactual PT/INR prolongation caused by daptomycin interaction with certain recombinant thromboplastin reagents.
Contraindications & Cautions
Absolute Contraindications
- Known hypersensitivity to daptomycin — anaphylaxis has been reported
Relative Contraindications (Specialist Input Recommended)
- Pneumonia (any cause) — daptomycin is inactivated by pulmonary surfactant; clinical trials for CAP showed higher mortality and lower cure rates with daptomycin than comparator. Do not use for pneumonia even if the pathogen is susceptible in vitro
- Left-sided infective endocarditis — not FDA-approved; clinical trial data did not demonstrate efficacy for left-sided IE. Off-label high-dose use with combination therapy may be considered by ID specialists in salvage situations
Use with Caution
- Renal impairment (CrCl <30 mL/min) — extend dosing interval to q48h; increased risk of CPK elevation and myopathy; decreased efficacy observed in cSSSI patients with CrCl <50 mL/min
- Concurrent HMG-CoA reductase inhibitors — consider suspending statins during daptomycin therapy; if continued, monitor CPK more frequently
- Pediatric patients <1 year — not recommended due to potential effects on muscular, neuromuscular, and nervous systems observed in neonatal dogs
- Prior or concurrent drugs causing myopathy — increased baseline risk of CPK elevation; monitor closely
In Phase 3 trials comparing daptomycin to ceftriaxone for community-acquired pneumonia, daptomycin-treated patients had lower cure rates and higher mortality. Daptomycin is inactivated by pulmonary surfactant, rendering it ineffective in the lung regardless of in vitro susceptibility. This contraindication applies to all forms of pneumonia, including CAP, HAP, and VAP.
Postmarketing reports of eosinophilic pneumonia have been associated with daptomycin use, typically presenting 2–4 weeks after initiation. Clinicians should be alert for new-onset fever, cough, dyspnoea, and pulmonary infiltrates in any patient receiving daptomycin. Peripheral eosinophilia and BAL eosinophilia support the diagnosis. Prompt discontinuation of daptomycin and corticosteroid therapy if needed usually leads to resolution. Do not rechallenge with daptomycin.
Patient Counselling
Purpose of Therapy
Daptomycin is a powerful antibiotic given through a vein (IV) to treat serious skin infections and bloodstream infections caused by resistant bacteria, including MRSA. It cannot be taken by mouth. Treatment may last from one to six weeks depending on the type and severity of your infection.
How It Is Given
Daptomycin is given as an IV infusion (over 30 minutes) or as an IV push (over 2 minutes) once daily. If you are receiving treatment at home through a PICC line, a home infusion nurse will teach you or your caregiver how to administer it safely. The medication must be mixed only with normal saline (0.9% sodium chloride) — never with dextrose-containing solutions.
Sources
- Cubicin (daptomycin for injection) — Full Prescribing Information. Merck Sharp & Dohme LLC. Revised 2025. FDA Label (2025)Most current FDA label with adult and pediatric indications (cSSSI and S. aureus bacteremia), dosing tables, CPK monitoring guidance, eosinophilic pneumonia warning, and renal dose adjustment.
- Cubicin (daptomycin for injection) — Prescribing Information. Revised 2018. FDA Label (2018)Earlier FDA label version with detailed PK parameters, adverse reaction tables from Phase 3 trials (cSSSI n=534; bacteremia n=120), and drug interaction data.
- Arbeit RD, Maki D, Tally FP, Campanaro E, Eisenstein BI. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis. 2004;38(12):1673–1681. doi:10.1086/420818Pivotal Phase 3 trial establishing daptomycin 4 mg/kg non-inferiority to comparator for cSSSI with adverse event rates including CPK elevation (2.8%).
- Fowler VG Jr, Boucher HW, Corey GR, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med. 2006;355(7):653–665. doi:10.1056/NEJMoa053783Landmark Phase 3 RCT establishing daptomycin 6 mg/kg non-inferiority to standard therapy (anti-staphylococcal penicillin or vancomycin + initial gentamicin) for S. aureus bacteremia including right-sided endocarditis.
- Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by IDSA for the treatment of MRSA infections in adults and children. Clin Infect Dis. 2011;52(3):e18–e55. doi:10.1093/cid/ciq146IDSA MRSA guideline recommending daptomycin for MRSA bacteremia and right-sided endocarditis (6 mg/kg), with consideration of higher doses (8–10 mg/kg) for persistent bacteremia.
- Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications. Circulation. 2015;132(15):1435–1486. doi:10.1161/CIR.0000000000000296AHA/IDSA guideline for infective endocarditis positioning daptomycin as an alternative for native and prosthetic valve MRSA right-sided endocarditis.
- Silverman JA, Perlmutter NG, Shapiro HM. Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus. Antimicrob Agents Chemother. 2003;47(8):2538–2544. doi:10.1128/AAC.47.8.2538-2544.2003Mechanistic study demonstrating daptomycin’s calcium-dependent membrane insertion and depolarisation as the basis for its rapid bactericidal activity.
- Sakoulas G, Bayer AS, Pogliano J, et al. Ampicillin enhances daptomycin- and cationic host defense peptide-mediated killing of ampicillin- and vancomycin-resistant Enterococcus faecium. Antimicrob Agents Chemother. 2012;56(2):838–844. doi:10.1128/AAC.05551-11Study establishing the synergistic mechanism of beta-lactam + daptomycin combination therapy against VRE and resistant enterococci.
- Dvorchik BH, Brazier D, DeBruin MF, Arbeit RD. Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects. Antimicrob Agents Chemother. 2003;47(4):1318–1323. doi:10.1128/AAC.47.4.1318-1323.2003Phase 1 PK study establishing linear pharmacokinetics through 6 mg/kg, half-life (~8 h), Vd (~0.1 L/kg), renal clearance, and the safety of once-daily dosing.
- Benvenuto M, Benziger DP, Yankelev S, Vigliani G. Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers. Antimicrob Agents Chemother. 2006;50(10):3245–3249. doi:10.1128/AAC.00247-06Phase 1 dose-escalation study confirming tolerability of daptomycin up to 12 mg/kg for 14 days, supporting the use of high-dose regimens in clinical practice.
- Bhavnani SM, Rubino CM, Ambrose PG, Drusano GL. Daptomycin exposure and the probability of elevations in the creatine phosphokinase level: data from a randomized trial of patients with bacteremia and endocarditis. Clin Infect Dis. 2010;50(12):1568–1574. doi:10.1086/652767PK/PD analysis from the bacteremia trial linking daptomycin trough concentrations (>24.3 mg/L) to increased CPK elevation risk, informing monitoring thresholds.
- Kim PW, Sorbello AF, Wassel RT, et al. Eosinophilic pneumonia in patients treated with daptomycin: review of the literature and US FDA adverse event reporting system reports. Drug Saf. 2012;35(6):447–457. doi:10.2165/11597460-000000000-00000Systematic review of daptomycin-associated eosinophilic pneumonia from FAERS data establishing clinical characteristics, typical onset, and outcomes.